updated 11/30/2010 8:16:51 AM ET 2010-11-30T13:16:51

DALLAS, Nov. 30, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/VVUS

VIVUS Inc. (VVUS) is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, obstructive sleep apnea and sexual health. Its lead product in clinical development, Qnexa, completed phase III clinical trials for the treatment of obesity and a New Drug Application (NDA) was filed and accepted by the Food and Drug Association (FDA). The Company received a Complete Response Letter (CRL) from the FDA and is preparing a written response to address the FDA's requests for information included in the CRL. Qnexa is also in phase II clinical trials for type 2 diabetes and obstructive sleep apnea. VVUS is also developing an erectile dysfunction drug, Avanafil, which is in phase III clinical trials.

Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS

In the report, the analyst notes:

"VVUS late last month received a Complete Response Letter (CRL) from the FDA regarding the Qnexa NDA. The Company said the FDA declined to approve Qnexa and asked a detailed plan to evaluate and mitigate risks in women of childbearing potential.

"'We remain confident in the efficacy and safety profile of Qnexa demonstrated in the clinical development program and look forward to continue working with the FDA toward the approval for the treatment of obesity,' said CEO Leland Wilson. The Company expects to complete its response to the FDA by the end of the year."

To read the entire report visit: www.microstockprofit.com/lp/VVUS

See what investors are saying about VVUS at http://www.stockhideout.com

Get breaking news on VVUS at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com